[构建中国血液学共同体]
[To construct Chinese hematology community].
作者信息
Huang X J, Xu Z L
机构信息
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematological Diseases, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation for the Treatment of Hematology, Beijing 100044, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2024 Jun 14;45(6):521-524. doi: 10.3760/cma.j.cn121090-20240523-00186.
Abstract
The development of hematology in China has gradually begun since the 1950s. After several generations of hard work, it has grown into a young but vibrant discipline. The development of Chinese hematology has experienced rapid rise and steady growth, but there is still a gap with the international level of hematology development. Only by constructing a Chinese community of hematology and forming a joint force to promote the development of hematology can we better realize the Chinese Dream in the field of hematology.
摘要
中国血液学的发展自20世纪50年代起逐步开始。经过几代人的努力，它已成长为一门年轻但充满活力的学科。中国血液学的发展经历了快速崛起和稳步增长，但与国际血液学发展水平仍存在差距。只有构建中国血液学共同体，形成推动血液学发展的合力，才能更好地实现血液学领域的中国梦。
相似文献
1
[To construct Chinese hematology community].
Zhonghua Xue Ye Xue Za Zhi. 2024 Jun 14;45(6):521-524. doi: 10.3760/cma.j.cn121090-20240523-00186.
2
[Healthy China 2030 critical care medicine: challenges accepted--40-year-chronicle of critical care medicine in China].
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019 Jul;31(7):793-800. doi: 10.3760/cma.j.issn.2095-4352.2019.07.001.
3
Hematologic health services and practical characteristics: report of a nationwide survey among Chinese hematologists.
BMC Health Serv Res. 2024 Mar 12;24(1):326. doi: 10.1186/s12913-024-10829-z.
4
Mutual benefit for foreign medical students and Chinese postgraduates: A mixed team-based learning method overcomes communication problems in hematology clerkship.
Biochem Mol Biol Educ. 2017 Mar 4;45(2):93-96. doi: 10.1002/bmb.20997. Epub 2016 Nov 1.
5
Hematology research output from Chinese authors and other countries: a 10-year survey of the literature.
J Hematol Oncol. 2015 Feb 6;8:8. doi: 10.1186/s13045-014-0103-3.
6
Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China.
Oncotarget. 2017 Jun 20;8(25):41620-41630. doi: 10.18632/oncotarget.15655.
7
Launching an International Community of Practice in Hematology/Oncology Medical Education.
Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e100046. doi: 10.1200/EDBK_100046.
8
[Benchmarking China's Top-Tier Medical Institutions Against Global Standards: A Quantitative Analysis of the Gap Using Internationally Recognized Metrics].
Sichuan Da Xue Xue Bao Yi Xue Ban. 2025 Jan 20;56(1):166-174. doi: 10.12182/20250160302.
9
Brief history of the Asiatic International Society of Hematology: our roots of international cooperation with Asian countries.
Int J Hematol. 2018 Dec;108(6):566-570. doi: 10.1007/s12185-018-2549-5. Epub 2018 Oct 12.
10
[Reduce the burden of disease, realize the health dream of Chinese].
Zhonghua Yu Fang Yi Xue Za Zhi. 2015 Apr;49(4):289-91.
本文引用的文献
1
CAR T-cell therapies in China: rapid evolution and a bright future.
Lancet Haematol. 2022 Dec;9(12):e930-e941. doi: 10.1016/S2352-3026(22)00291-5.
2
Haematopoietic stem-cell transplantation in China in the era of targeted therapies: current advances, challenges, and future directions.
Lancet Haematol. 2022 Dec;9(12):e919-e929. doi: 10.1016/S2352-3026(22)00293-9.
3
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.
J Hematol Oncol. 2022 Aug 18;15(1):113. doi: 10.1186/s13045-022-01334-z.
4
Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial.
Lancet Haematol. 2022 Jul;9(7):e504-e513. doi: 10.1016/S2352-3026(22)00113-2. Epub 2022 May 19.
5
A novel NPM1-RARG-NPM1 chimeric fusion in acute myeloid leukaemia resembling acute promyelocytic leukaemia but resistant to all-trans retinoic acid and arsenic trioxide.
Br J Cancer. 2019 May;120(11):1023-1025. doi: 10.1038/s41416-019-0456-z. Epub 2019 Apr 18.
6
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet.
Blood. 2019 Apr 11;133(15):1630-1643. doi: 10.1182/blood-2019-01-894980. Epub 2019 Feb 25.
7
Identification of novel recurrent CPSF6-RARG fusions in acute myeloid leukemia resembling acute promyelocytic leukemia.
Blood. 2018 Apr 19;131(16):1870-1873. doi: 10.1182/blood-2017-11-818716. Epub 2018 Feb 27.
8
Identification of novel recurrent - fusions in acute promyelocytic leukemia lacking t(15;17)(q22;q12)/-.
Blood. 2018 Feb 22;131(8):935-939. doi: 10.1182/blood-2017-09-807370. Epub 2017 Dec 13.
9
The Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell Transplantation.
Biol Blood Marrow Transplant. 2016 Oct;22(10):1747-1757. doi: 10.1016/j.bbmt.2016.07.003. Epub 2016 Jul 11.
10
Haploidentical transplantation: the search for the best donor.
Blood. 2014 Aug 7;124(6):827-8. doi: 10.1182/blood-2014-06-582460.
Zotero 插件